Arteriosclerosis is a type of cardiovascular disorder characterised by build-up of plaque inside arteries. Plaques are generally made up of fat, calcium, cholesterol, and other substances in the blood. The plaque formation leads to decrease in supply of oxygen-rich blood to the organs in the body. The complications associated with arteriosclerosis include stroke and heart attack. Some of the risk factors associated with arteriosclerosis are high blood pressure, insulin resistance, diabetes, obesity, lack of physical activity, and family history. Arteriosclerosis can be symptomatized by confusion, facial numbness, sudden weakness, and difficulty in understanding speech. MedImmune LLC is in the process of developing MEDI6012 as an apolipoprotein A I stimulant for the treatment of arteriosclerosis. Guangzhou Yipinhong Pharmaceutical Co., Ltd. is in the process of developing alprostadil as a prostaglandin E1 agonist for the treatment of arteriosclerosis. Some of the companies having the pipeline of arteriosclerosis include Guangzhou Yipinhong Pharmaceutical Co., Ltd., Immunitor LLC, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.